In today's Pharmaceutical Executive Daily, FDA approves Ennumo, a pharma roundup covers Chemomab Therapeutics' merger with AI ...

FDA cleared Ennumo as a Neulasta biosimilar for febrile neutropenia prophylaxis in non-myeloid malignancy patients receiving myelosuppressive chemotherapy, including pediatric populations from ...

Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...

Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of ...

Jay Bregman, CEO and co-founder of Andel, discusses how FDA’s action signals a broader regulatory recalibration aimed at protecting intellectual property and explores the second-order effects. Jay ...

Bansi Nagji, CEO of PANTHERx Rare, explores how innovation is increasingly directed toward rare and orphan diseases, driven ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

Novartis filed New Jersey notices for 322 East Hanover layoffs starting October 2, after earlier filings for 76 cuts at the same site. Disclosures to date do not specify impacted functions, job ...

Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...

A joint framework is being built to convert Israeli academic target biology into viable small-molecule programs by integrating AI-enabled design with rigorous experimental validation. ChemPass AI™ ...

It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...

For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial ...